Quinolones: a Class of Antimicrobial Agents
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Partners in Practice
ADRENALS: Spring 2012 What you won’t find in a textbook Partners in Practice Dr Sue Foster BVSc, MVetClinStud, FACVSc Vetnostics Small Animal Medical Consultant ➤ Cutaneous Mycobacterial Disease in Dogs and Cats: Part 2 PART 4b: UCCr and CALP ➤ The Most Difficult and Frustrating Diagnoses As part 4 of this series looks at diagnostic tests, we can’t Corticosteroid-induced alkaline phosphatase escape some statistics. So, some very simplistic explanations (c-ALP) relative to hyperA are as follows: ➤ Adrenals: Part 4b Increased serum ALP, the most common routine laboratory Sensitivity: the likelihood that the test will detect hyperA abnormality in hyperA is due mainly to the induction Specificity: the chance that a positive test is truly hyperA of a specific ALP isoenzyme by glucocorticoids. The corticosteroid-induced isoenzyme of ALP can be measured Then, there are predictive values which take into account by electrophoretic separation, heat inactivation or more the prevalence or likelihood of a disease in addition to usually in commercial laboratories, by levamisole-inhibition. sensitivity and specificity. The levamisole inhibition explains why c-ALP is sometimes referred to as l-ALP but this terminology can be confusing Positive predictive value (PPV): the chance of a positive as sometimes l-ALP is used to describe the liver isoenzyme; result being indicative of hyperA in dogs with signs of it is also referred to as CAP (corticosteroid-induced ALP) or hyperA (e.g. Can we confidently diagnose hyperA when we SIAP (steroid-induced alkaline phosphatase). get a “positive” result?) The sensitivity of c-ALP has been reported to be 0.81-0.95.7-9 Negative predictive value (NPV): the likelihood that a Specificity is poor (0.18-0.44)7-9 and PPV in one study was negative results eliminates the possibility of hyperA in dogs as low as 21.4%7 thus this test cannot be recommended as with signs of hyperA (e.g. -
Clinically Isolated Chlamydia Trachomatis Strains
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, JUIY 1988, p. 1080-1081 Vol. 32, No. 7 0066-4804/88/071080-02$02.00/0 Copyright © 1988, American Society for Microbiology In Vitro Activities of T-3262, NY-198, Fleroxacin (AM-833; RO 23-6240), and Other New Quinolone Agents against Clinically Isolated Chlamydia trachomatis Strains HIROSHI MAEDA,* AKIRA FUJII, KATSUHISA NAKATA, SOICHI ARAKAWA, AND SADAO KAMIDONO Department of Urology, School of Medicine, Kobe University, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe-city, Japan Received 9 December 1987/Accepted 29 March 1988 The in vitro activities of three newly developed quinolone drugs (T-3262, NY-198, and fleroxacin [AM-833; RO 23-6240]) against 10 strains of clinically isolated Chiamydia trachomatis were assessed and compared with those of other quinolones and minocycline. T-3262 (MIC for 90% of isolates tested, 0.1 ,ug/ml) was the most active of the quinolones. The NY-198 and fleroxacin MICs for 90% of isolates were 3.13 and 62.5 ,ug/ml, respectively. Recently, it has become well known that Chlamydia 1-ml sample of suspension was seeded into flat-bottomed trachomatis is an important human pathogen. It is respon- tubes with glass cover slips and incubated at 37°C in 5% CO2 sible not only for trachoma but also for sexually transmitted for 24 h. The monolayer was inoculated with 103 inclusion- infections, including lymphogranuloma venereum. In forming units of C. trachomatis. The tubes were centrifuged women, it causes cervicitis, endometritis, and salpingitis at 2,000 x g at 25°C for 45 min and left undisturbed at room asymptomatically (19), while in men it causes nongono- temperature for 2 h. -
A TWO-YEAR RETROSPECTIVE ANALYSIS of ADVERSE DRUG REACTIONS with 5PSQ-031 FLUOROQUINOLONE and QUINOLONE ANTIBIOTICS 24Th Congress Of
A TWO-YEAR RETROSPECTIVE ANALYSIS OF ADVERSE DRUG REACTIONS WITH 5PSQ-031 FLUOROQUINOLONE AND QUINOLONE ANTIBIOTICS 24th Congress of V. Borsi1, M. Del Lungo2, L. Giovannetti1, M.G. Lai1, M. Parrilli1 1 Azienda USL Toscana Centro, Pharmacovigilance Centre, Florence, Italy 2 Dept. of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), 27-29 March 2019 Section of Pharmacology and Toxicology , University of Florence, Italy BACKGROUND PURPOSE On 9 February 2017, the Pharmacovigilance Risk Assessment Committee (PRAC) initiated a review1 of disabling To review the adverse drugs and potentially long-lasting side effects reported with systemic and inhaled quinolone and fluoroquinolone reactions (ADRs) of antibiotics at the request of the German medicines authority (BfArM) following reports of long-lasting side effects systemic and inhaled in the national safety database and the published literature. fluoroquinolone and quinolone antibiotics that MATERIAL AND METHODS involved peripheral and central nervous system, Retrospective analysis of ADRs reported in our APVD involving ciprofloxacin, flumequine, levofloxacin, tendons, muscles and joints lomefloxacin, moxifloxacin, norfloxacin, ofloxacin, pefloxacin, prulifloxacin, rufloxacin, cinoxacin, nalidixic acid, reported from our pipemidic given systemically (by mouth or injection). The period considered is September 2016 to September Pharmacovigilance 2018. Department (PVD). RESULTS 22 ADRs were reported in our PVD involving fluoroquinolone and quinolone antibiotics in the period considered and that affected peripheral or central nervous system, tendons, muscles and joints. The mean patient age was 67,3 years (range: 17-92 years). 63,7% of the ADRs reported were serious, of which 22,7% caused hospitalization and 4,5% caused persistent/severe disability. 81,8% of the ADRs were reported by a healthcare professional (physician, pharmacist or other) and 18,2% by patient or a non-healthcare professional. -
A Review of Enrofloxacin for Veterinary Use Tessa Trouchon, Sebastien Lefebvre
A Review of Enrofloxacin for Veterinary Use Tessa Trouchon, Sebastien Lefebvre To cite this version: Tessa Trouchon, Sebastien Lefebvre. A Review of Enrofloxacin for Veterinary Use. Open Journal of Veterinary Medicine, 2016, 6 (2), pp.40-58. 10.4236/ojvm.2016.62006. hal-01503397 HAL Id: hal-01503397 https://hal.archives-ouvertes.fr/hal-01503397 Submitted on 7 Apr 2017 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Distributed under a Creative Commons Attribution - NoDerivatives| 4.0 International License Open Journal of Veterinary Medicine, 2016, 6, 40-58 Published Online February 2016 in SciRes. http://www.scirp.org/journal/ojvm http://dx.doi.org/10.4236/ojvm.2016.62006 A Review of Enrofloxacin for Veterinary Use Tessa Trouchon, Sébastien Lefebvre USC 1233 INRA-Vetagro Sup, Veterinary School of Lyon, Marcy l’Etoile, France Received 12 January 2016; accepted 21 February 2016; published 26 February 2016 Copyright © 2016 by authors and Scientific Research Publishing Inc. This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/ Abstract This review outlines the current knowledge on the use of enrofloxacin in veterinary medicine from biochemical mechanisms to the use in the field conditions and even resistance and ecotoxic- ity. -
Pharmacology
FORM UPDATED | 04/07/20 Pharmacology 865-974-5646 Diagnostic Laboratory Service For lab Date Received: # of Samples Received: vetmed.tennessee.edu/vmc/dls use only Institution/Practice: ASSAYS CURRENTLY AVAILABLE Veterinarian: Aciclovir Gabapentin Address: Amoxicillin Galliprant Bromide Ganciclovir Bupivacaine Hydromorphone Butorphanol Itraconazole & Hydroxyitraconazole Carboplatin Ivermectin Phone: Caffeine Ketamine & Norketamine Fax: Carprofen Ketoprofen Carvedilol Lidocaine & metabolites Type of Sample: Ceftiofur Meloxicam No. of Samples: Ceftiofur Equivalents Midazolam & Hydroxmidazolam Cefovecin Metronidazole Date &Time Dosed: Chloramphenicol Moxidectin Citrate (urine only) Omeprazole Date & Time Collected: Deracoxib Oxalate (urine only) Dosage Amount: Diazepam and Nordiazepam Oxytetracycline Famciclovir/Penciclovir Piroxicam Dosage Formulation: Fenbendazole Praziquantil Route: Fentanyl Prednisolone Firocoxib Propofol Sample Identification Info: Flunixin Robenacoxib Species: Canine Feline Equine Fluconazole Terbinafine Other:__________________________________________________________ Fluoroquinolones: Thiafentanil Medication History (All medications the animal is currently on or has recently received): Ciprofloxacin Tramadol and metabolites Enrofloxacin M1, M2, M4, & M5 Fleroxacin Uric Acid Marbofloxacin Valciclovir Moxifloxacin Voriconazole Furosemide Requested Assay: If you are interested in drugs not listed, contact the laboratory with questions about assay development and cost. Ship Samples to: UTCVM Pharmacology Laboratory 2407 -
Multi-Residual Quantitative Analytical Method for Antibiotics in Sea Food by LC/MS/MS
PO-CON1742E Multi-residual quantitative analytical method for antibiotics in sea food by LC/MS/MS ASMS 2017 TP 198 Anant Lohar, Shailendra Rane, Ashutosh Shelar, Shailesh Damale, Rashi Kochhar, Purushottam Sutar, Deepti Bhandarkar, Ajit Datar, Pratap Rasam and Jitendra Kelkar Shimadzu Analytical (India) Pvt. Ltd., 1 A/B, Rushabh Chambers, Makwana Road, Marol, Andheri (E), Mumbai-400059, Maharashtra, India. Multi-residual quantitative analytical method for antibiotics in sea food by LC/MS/MS Introduction Antibiotics are widely used in agriculture as growth LC/MS/MS method has been developed for quantitation of enhancers, disease treatment and control in animal feeding multi-residual antibiotics (Table 1) from sea food sample operations. Concerns for increased antibiotic resistance of using LCMS-8040, a triple quadrupole mass spectrometer microorganisms have prompted research into the from Shimadzu Corporation, Japan. Simultaneous analysis environmental occurrence of these compounds. of multi-residual antibiotics often exhibit peak shape Assessment of the environmental occurrence of antibiotics distortion owing to their different chemical nature. To depends on development of sensitive and selective overcome this, autosampler pre-treatment feature was analytical methods based on new instrumental used [1]. technologies. Table 1. List of antibiotics Sr.No. Name of group Name of compound Number of compounds Flumequine, Oxolinic Acid, Ciprofloxacin, Danofloxacin, Difloxacin.HCl, 1 Fluoroquinolones 8 Enrofloxacin, Sarafloxacin HCl Trihydrate, -
Antibiotic Use Guidelines for Companion Animal Practice (2Nd Edition) Iii
ii Antibiotic Use Guidelines for Companion Animal Practice (2nd edition) iii Antibiotic Use Guidelines for Companion Animal Practice, 2nd edition Publisher: Companion Animal Group, Danish Veterinary Association, Peter Bangs Vej 30, 2000 Frederiksberg Authors of the guidelines: Lisbeth Rem Jessen (University of Copenhagen) Peter Damborg (University of Copenhagen) Anette Spohr (Evidensia Faxe Animal Hospital) Sandra Goericke-Pesch (University of Veterinary Medicine, Hannover) Rebecca Langhorn (University of Copenhagen) Geoffrey Houser (University of Copenhagen) Jakob Willesen (University of Copenhagen) Mette Schjærff (University of Copenhagen) Thomas Eriksen (University of Copenhagen) Tina Møller Sørensen (University of Copenhagen) Vibeke Frøkjær Jensen (DTU-VET) Flemming Obling (Greve) Luca Guardabassi (University of Copenhagen) Reproduction of extracts from these guidelines is only permitted in accordance with the agreement between the Ministry of Education and Copy-Dan. Danish copyright law restricts all other use without written permission of the publisher. Exception is granted for short excerpts for review purposes. iv Foreword The first edition of the Antibiotic Use Guidelines for Companion Animal Practice was published in autumn of 2012. The aim of the guidelines was to prevent increased antibiotic resistance. A questionnaire circulated to Danish veterinarians in 2015 (Jessen et al., DVT 10, 2016) indicated that the guidelines were well received, and particularly that active users had followed the recommendations. Despite a positive reception and the results of this survey, the actual quantity of antibiotics used is probably a better indicator of the effect of the first guidelines. Chapter two of these updated guidelines therefore details the pattern of developments in antibiotic use, as reported in DANMAP 2016 (www.danmap.org). -
AMEG Categorisation of Antibiotics
12 December 2019 EMA/CVMP/CHMP/682198/2017 Committee for Medicinal Products for Veterinary use (CVMP) Committee for Medicinal Products for Human Use (CHMP) Categorisation of antibiotics in the European Union Answer to the request from the European Commission for updating the scientific advice on the impact on public health and animal health of the use of antibiotics in animals Agreed by the Antimicrobial Advice ad hoc Expert Group (AMEG) 29 October 2018 Adopted by the CVMP for release for consultation 24 January 2019 Adopted by the CHMP for release for consultation 31 January 2019 Start of public consultation 5 February 2019 End of consultation (deadline for comments) 30 April 2019 Agreed by the Antimicrobial Advice ad hoc Expert Group (AMEG) 19 November 2019 Adopted by the CVMP 5 December 2019 Adopted by the CHMP 12 December 2019 Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. Categorisation of antibiotics in the European Union Table of Contents 1. Summary assessment and recommendations .......................................... 3 2. Introduction ............................................................................................ 7 2.1. Background ........................................................................................................ -
Mitigation of Antimicrobial Drug Resistance and Changes in The
Mitigation of Antimicrobial Drug Resistance and Changes in the Microbiome of Feedlot Cattle Supplemented with Lactobacillus salivarius L28 as an Alternative to Sub-Therapeutic Antibiotics by Andrea R. English, M.S. A Dissertation In Animal Science Submitted to the Graduate Faculty of Texas Tech University in Partial Fulfillment of the Requirements for the Degree of DOCTOR OF PHILOSOPHY Approved Dr. Marcos X. Sánchez-Plata Co-Chair of Committee Dr. Mindy M. Brashears Co-Chair of Committee Dr. Kendra K. Nightingale Dr. Alejandro Echeverry Dr. Jessie Vipham Dr. Mark F. Miller Mark Sheridan Dean of the Graduate School December, 2019 Copyright 2019, Andrea English Texas Tech University, Andrea English, December 2019 ACKNOWLEDGMENTS I would like to first thank my advisor Dr. Mindy Brashears you took a chance on me and I am forever grateful. I am so thankful that I was able to learn and grow as a scientist under your guidance. You have provided me with experiences I will always remember. Thank you for everything you have done for me while at Texas Tech. Thank you to my committee, Dr. Sanchez you have been an incredible mentor and I have truly valued absorbing as much knowledge as I possibly could from you. Dr. Nightingale thank you for investing in me and this project. You pushed me to be a better scientist which I very much appreciate. Dr. Echeverry and Dr. Vipham I cannot say thank you enough for the support you have provided me. You each have always made time for me and that is invaluable. Dr. Miller thank you for continuously providing me with opportunities to grow, learn and dabble in meat science while here at Texas Tech. -
WSAVA List of Essential Medicines for Cats and Dogs
The World Small Animal Veterinary Association (WSAVA) List of Essential Medicines for Cats and Dogs Version 1; January 20th, 2020 Members of the WSAVA Therapeutic Guidelines Group (TGG) Steagall PV, Pelligand L, Page SW, Bourgeois M, Weese S, Manigot G, Dublin D, Ferreira JP, Guardabassi L © 2020 WSAVA All Rights Reserved Contents Background ................................................................................................................................... 2 Definition ...................................................................................................................................... 2 Using the List of Essential Medicines ............................................................................................ 2 Criteria for selection of essential medicines ................................................................................. 3 Anaesthetic, analgesic, sedative and emergency drugs ............................................................... 4 Antimicrobial drugs ....................................................................................................................... 7 Antibacterial and antiprotozoal drugs ....................................................................................... 7 Systemic administration ........................................................................................................ 7 Topical administration ........................................................................................................... 9 Antifungal drugs ..................................................................................................................... -
Nitroaromatic Antibiotics As Nitrogen Oxide Sources
Review biomolecules Nitroaromatic Antibiotics as Nitrogen Oxide Sources Review Allison M. Rice, Yueming Long and S. Bruce King * Nitroaromatic Antibiotics as Nitrogen Oxide Sources Department of Chemistry and Biochemistry, Wake Forest University, Winston-Salem, NC 27101, USA; Allison M. Rice , Yueming [email protected] and S. Bruce (A.M.R.); King [email protected] * (Y.L.) * Correspondence: [email protected]; Tel.: +1-336-702-1954 Department of Chemistry and Biochemistry, Wake Forest University, Winston-Salem, NC 27101, USA; [email protected]: Nitroaromatic (A.M.R.); [email protected] antibiotics (Y.L.) show activity against anaerobic bacteria and parasites, finding * Correspondence: [email protected]; Tel.: +1-336-702-1954 use in the treatment of Heliobacter pylori infections, tuberculosis, trichomoniasis, human African trypanosomiasis, Chagas disease and leishmaniasis. Despite this activity and a clear need for the Abstract: Nitroaromatic antibiotics show activity against anaerobic bacteria and parasites, finding usedevelopment in the treatment of new of Heliobacter treatments pylori forinfections, these conditio tuberculosis,ns, the trichomoniasis, associated toxicity human Africanand lack of clear trypanosomiasis,mechanisms of action Chagas have disease limited and their leishmaniasis. therapeutic Despite development. this activity Nitroaro and a clearmatic need antibiotics for require thereductive development bioactivation of new treatments for activity for theseand this conditions, reductive the associatedmetabolism toxicity can convert -
FLUOROQUINOLONES: from Structure to Activity and Toxicity
FLUOROQUINOLONES: from structure to activity and toxicity F. Van Bambeke, Pharm. D. & P. M. Tulkens, MD, PhD Unité de Pharmacologie Cellulaire et Moléculaire Université Catholique de Louvain, Brussels, Belgium SBIMC / BVIKM www.sbimc.org - www.bvikm.org www.md.ucl.ac.be/facm www.isap.org soon... Mechanism of action of fluoroquinolones: the basics... PORIN DNA Topo DNA gyrase isomerase Gram (-) Gram (+) 2 key enzymes in DNA replication: DNA gyrase topoisomerase IV bacterial DNA is supercoiled Ternary complex DNA - enzyme - fluoroquinolone DNA GYRASE catalytic subunits COVALENTLY CLOSED CIRCULAR DNA FLUOROQUINOLONES: DNA GYRASE ATP binding subunits 4 stacked molecules (Shen, in Quinolone Antimicrobial Agents, 1993) Resistance to fluoroquinolones: the basics decreased efflux pump permeability DNA mutation of DNA gyrase Topo isomerase the enzymes Gram (-) Gram (+) Fluoroquinolones are the first entirely man-made antibiotics: do we understand our molecule ? R5 O R COOH 6 R7 X8 N R1 Don’t panic, we will travel together…. Chemistry and Activity This is where all begins... The pharmacophore common to all fluoroquinolones BINDING TO DNA R5 O O R C 6 - BINDING TO O BINDING TO THE ENZYME THE ENZYME R7 X8 N R1 AUTO-ASSEMBLING DOMAIN (for stacking) From chloroquine to nalidixic acid... nalidixic acid N CH3 O O HN CH 3 C - O chloroquine CH N N Cl N 3 C2H5 1939 O O C O- 1962 Cl N 1958 C2H5 7-chloroquinoline (synthesis intermediate found to display antibacterial activity) Nalidixic acid * a • typical chemical features of O O fluoroquinolones (a, b, c) BUT a naphthridone C - O- b (N at position 8: ) H C N N 3 • limited usefulness as drug C H 2 5 • narrow antibacterial spectrum c (Enterobacteriaceae only) • short half-life (1.5h) • high protein binding (90%) * Belg.